Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
Eyenovia (NASDAQ: EYEN), an ophthalmic technology company focused on its proprietary Optejet medication dispensing platform, will release its Q3 2024 financial results on Tuesday, November 12th, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results. Investors can join via phone (1-877-407-9039 domestic, 1-201-689-8470 international) or through the company's website. The webcast will be archived for one year on Eyenovia's website.
Eyenovia (NASDAQ: EYEN), un'azienda tecnologica oftalmica focalizzata sulla sua piattaforma di somministrazione di farmaci Optejet, pubblicherà i suoi risultati finanziari del Q3 2024 martedì 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e un webcast alle 16:30 ET per discutere i risultati. Gli investitori possono partecipare telefonicamente (1-877-407-9039 nazionale, 1-201-689-8470 internazionale) oppure tramite il sito web dell'azienda. Il webcast sarà archiviato per un anno sul sito di Eyenovia.
Eyenovia (NASDAQ: EYEN), una empresa de tecnología oftálmica centrada en su plataforma de dispensación de medicamentos Optejet, publicará sus resultados financieros del Q3 2024 el martes 12 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m. ET para discutir los resultados. Los inversores pueden unirse por teléfono (1-877-407-9039 nacional, 1-201-689-8470 internacional) o a través del sitio web de la empresa. El webcast se archivará durante un año en el sitio web de Eyenovia.
Eyenovia (NASDAQ: EYEN)는 자사 고유의 Optejet 약물 배포 플랫폼에 중점을 둔 안과 기술 회사로, 2024년 3분기 재무 결과를 2024년 11월 12일 화요일, 시장 종료 후에 발표할 예정입니다. 회사는 결과를 논의하기 위해 동부 표준시 4:30 PM에 컨퍼런스 콜 및 웹캐스트를 진행합니다. 투자자는 전화(국내: 1-877-407-9039, 국제: 1-201-689-8470) 또는 회사 웹사이트를 통해 참여할 수 있습니다. 웹캐스트는 Eyenovia 웹사이트에서 1년 동안 보관됩니다.
Eyenovia (NASDAQ: EYEN), une entreprise de technologie ophtalmique axée sur sa plateforme de distribution de médicaments Optejet, publiera ses résultats financiers du T3 2024 le mardi 12 novembre 2024, après la fermeture du marché. L'entreprise organisera un appel conférence et un webinaire à 16h30 HE pour discuter des résultats. Les investisseurs peuvent participer par téléphone (1-877-407-9039 nationale, 1-201-689-8470 internationale) ou via le site Web de l'entreprise. Le webinaire sera archivé pendant un an sur le site d'Eyenovia.
Eyenovia (NASDAQ: EYEN), ein Unternehmen für Augenheilkunde, das sich auf seine eigene Medikamentenabgabetechnologie Optejet konzentriert, wird seine Finanzergebnisse für das Q3 2024 am Dienstag, dem 12. November 2024, nach Börsenschluss veröffentlichen. Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast durchführen, um die Ergebnisse zu besprechen. Investoren können telefonisch teilnehmen (1-877-407-9039 national, 1-201-689-8470 international) oder über die Website des Unternehmens. Der Webcast wird ein Jahr lang auf der Website von Eyenovia archiviert.
- None.
- None.
Company to host an investor conference call and webcast at 4:30pm EDT
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that the Company will release financial results for the third quarter ended September 30, 2024 on Tuesday, November 12th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial and operating results.
Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and reference Conference ID# 13748714.
To access the Call me™ feature, which avoids having to wait for an operator, click here.
A live webcast of the conference call will also be available here and on the investor relations page of the Company's corporate website at www.eyenovia.com.
After the live webcast, the event will be archived on Eyenovia’s website for one year.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. The company’s pre-NDA candidate, MicroPine, is being developed for pediatric progressive myopia, a global epidemic impacting hundreds of millions of children worldwide and representing a multi-billion-dollar addressable market. The company’s current commercial portfolio includes clobetasol propionate ophthalmic suspension,
For more information, visit Eyenovia.com.
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Eyenovia Contact:
Eyenovia, Inc.
Andrew Jones
Chief Financial Officer
ajones@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
FAQ
When will Eyenovia (EYEN) release Q3 2024 earnings?
How can I join Eyenovia's (EYEN) Q3 2024 earnings call?